No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .
L-Carnitine supplementation improved clinical status without changing oxidative stress and lipid profile in women with knee osteoarthritis.
Considering the pathologic importance of oxidative stress and altered lipid metabolism in osteoarthritis ( OA ) , this study aim ed to investigate the effect of l-carnitine supplementation on oxidative stress , lipid profile , and clinical status in women with knee OA . We hypothesized that l-carnitine would improve clinical status by modulating serum oxidative stress and lipid profile . In this r and omized double-blind , placebo-controlled trial , 72 overweight or obese women with mild to moderate knee OA were r and omly allocated into 2 groups to receive 750 mg/d l-carnitine or placebo for 8 weeks . Dietary intake was evaluated using 24-hour recall for 3 days . Serum malondialdehyde ( MDA ) , total antioxidant capacity ( TAC ) and lipid profile , visual analog scale for pain intensity , and patient global assessment of severity of disease were assessed before and after supplementation . Only 69 patients ( 33 in the l-carnitine group and 36 in the placebo group ) completed the study . l-Carnitine supplementation result ed in significant reductions in serum MDA ( 2.46 ± 1.13 vs 2.16 ± 0.94 nmol/mL ) , total cholesterol ( 216.09 ± 34.54 vs 206.12 ± 39.74 mg/dL ) , and low-density lipoprotein cholesterol ( 129.45 ± 28.69 vs 122.05 ± 32.76 mg/dL ) levels compared with baseline ( P < .05 ) , whereas these parameters increased in the placebo group . Serum triglyceride , high-density lipoprotein cholesterol , and TAC levels did not change significantly in both groups ( P > .05 ) . No significant differences were observed in dietary intake , serum lipid profile , MDA , and TAC levels between groups after adjusting for baseline values and covariates ( P > .05 ) . There were significant intragroup and intergroup differences in pain intensity and patient global assessment of disease status after supplementation ( P < .05 ) . Collectively , l-carnitine improved clinical status without changing oxidative stress and lipid profile significantly in women with knee OA
No significant effect was seen for waist circumference ( WC ) and body fat percent .
A non-linear dose-response association was seen between l-carnitine supplementation and body weight reduction ( P < 0.001 ) suggesting that ingestion of 2000 mg l-carnitine per day provides the maximum effect in adults .
This association was not seen for BMI , WC and body fat percent .
CONCLUSIONS l-carnitine supplementation provides a modest reducing effect on body weight , BMI and fat mass , especially among adults with overweight/obesity
BACKGROUND AND AIM Clinical evidence which investigated the effects of l-carnitine , a vitamin-like substance , on weight loss had led to inconsistent results .
This study therefore aim ed to examine the effect of l-carnitine supplementation on body weight and composition by including the maximum number of r and omized controlled trials ( RCTs ) and to conduct a dose-response analysis , for the first time .